We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

68 hedge funds and large institutions have $91.2M invested in Aevi Genomic Medicine Inc in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 28 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 13

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less capital invested

Capital invested by funds: $94.1M → $91.2M (-$2.95M)

1% less funds holding

Funds holding: 69 → 68 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

Holders
68
Holders Change
-1
Holders Change %
-1.45%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
28
Reduced
13
Closed
7
Calls
$379K
Puts
–
Net Calls
+$379K
Net Calls Change
+$280K

Top Buyers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
+$1.65M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$649K
3
BFA
BlackRock Fund Advisors
California
+$638K
4
NCMW
Northern Capital Management (Wisconsin)
Wisconsin
+$205K
5
BC
Birchview Capital
Vermont
+$194K

Top Sellers

Rank Fund Capital Flow
1
QF
QVT Financial
New York
-$4.14M
2
OM
Opaleye Management
Massachusetts
-$855K
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$555K
4
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$444K
5
UOC
UBS O'Connor
Illinois
-$278K
Name Holding Trade Value Shares
Change 		Change in
Stake
TA
26
Teachers Advisors
New York
$219K +$28.8K +5,060 +15%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$203K – – –
NCMW
28
Northern Capital Management (Wisconsin)
Wisconsin
$200K +$205K +35,950 New
BC
29
Birchview Capital
Vermont
$189K +$194K +34,000 New
CD
30
Carl Domino
Florida
$179K – – –
RhumbLine Advisers
31
RhumbLine Advisers
Massachusetts
$138K -$50.7K -8,900 -26%
Goldman Sachs
32
Goldman Sachs
New York
$130K +$37.9K +6,641 +40%
NFA
33
Nationwide Fund Advisors
Ohio
$115K +$39.7K +6,956 +51%
WPC
34
White Pine Capital
Minnesota
$111K – – –
VanEck Associates
35
VanEck Associates
New York
$88K +$331 +58 +0.4%
BA
36
BlackRock Advisors
Delaware
$87K +$25.8K +4,522 +41%
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$86K – – –
CDH
38
Charles D. Hyman
$84K – – –
BFM
39
Boothbay Fund Management
New York
$84K +$86.5K +15,170 New
AIG
40
American International Group
New York
$78.2K +$120 +21 +0.1%
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$78K +$45.5K +7,987 +129%
Wells Fargo
42
Wells Fargo
California
$74K -$4.28K -750 -5%
OAM
43
Oxford Asset Management
United Kingdom
$63K -$67.2K -11,792 -51%
Morgan Stanley
44
Morgan Stanley
New York
$60K +$26.5K +4,649 +76%
CS
45
Credit Suisse
Switzerland
$56K -$12.8K -2,245 -18%
CG
46
Cutler Group
California
$36K -$2.05K -360 -5%
PVH
47
Psagot Value Holdings
Israel
$34K -$9.7K -1,702 -22%
SO
48
STRS Ohio
Ohio
$28K -$1.14K -200 -4%
Creative Planning
49
Creative Planning
Kansas
$28K +$11.4K +2,000 +67%
UBS Group
50
UBS Group
Switzerland
$27K +$17K +2,976 +170%
1
2
3

GNMX Hedge Fund Activity: Q3 2016 in Review

68 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q3 2016, worth a combined $91.2M — down 3.1% from $94.1M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of GNMX and 6 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 28 added.

The largest buyer was Casdin Capital, adding an estimated $1.65M. The largest seller was QVT Financial, cutting an estimated $4.14M.

  • 68 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q3 2016, down from 69 in Q2 2016.
  • Funds reported $91.2M of Aevi Genomic Medicine Inc stock for Q3 2016, down 3.1% quarter-over-quarter.
  • 6 funds opened new Aevi Genomic Medicine Inc positions in Q3 2016 and 7 closed out, a net change of -1 holder.
  • The largest Aevi Genomic Medicine Inc buyer in Q3 2016 was Casdin Capital, an estimated $1.65M added.
  • The largest Aevi Genomic Medicine Inc seller in Q3 2016 was QVT Financial, an estimated $4.14M sold.

Based on aggregated 13F filings for Q3 2016.